Marksans Pharma Ltd

Marksans Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Marksans Pharma Ltd

₹ 82.8 -1.72%
02 Jun - close price
marksanspharma.com BSE: 524404 NSE : MARKSANS
About

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.

Our key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others. [1]

Key Points

Revenue Mix
Revenue Mix by therapeutic segment in FY22
Around 51% comes from Pain Management, 11% comes from Cough & Cold, 8% comes from Cardiovascular System, 6% comes from Gastrointestinal, and the rest comes from Anti-Diabetic, AntiAllergic, etc.
Revenue by delivery system
OTC: ~69% in FY22 compared to ~59% in FY21
RX: ~31% in FY22 compared to ~41% in FY21 [1]

Website BSE NSE
  • Market Cap ₹ 3,753 Cr.
  • Current Price ₹ 82.8
  • High / Low ₹ 87.7 / 38.6
  • Stock P/E 14.1
  • Book Value ₹ 38.5
  • Dividend Yield 0.60 %
  • ROCE 22.5 %
  • ROE 18.6 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 51.7% CAGR over last 5 years

Cons

  • Promoter holding has decreased over last quarter: -5.15%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
335 331 356 358 330 349 361 363 418 434 453 480 486
266 261 273 267 235 272 301 305 354 361 372 403 376
Operating Profit 69 70 83 91 95 77 60 58 64 73 80 77 110
OPM % 21% 21% 23% 25% 29% 22% 17% 16% 15% 17% 18% 16% 23%
0 0 4 -3 6 6 9 12 15 16 14 18 11
Interest 2 2 2 2 3 1 2 1 5 2 3 2 2
Depreciation 10 7 19 9 1 7 7 9 21 11 14 13 14
Profit before tax 58 61 66 78 97 75 60 60 53 76 78 79 104
Tax % 26% 20% 23% 24% 18% 16% 23% 20% 44% 21% 23% 21% 21%
Net Profit 43 49 51 59 80 63 46 48 30 60 60 62 83
EPS in Rs 1.04 1.21 1.24 1.44 1.94 1.53 1.11 1.18 0.69 1.46 1.51 1.57 1.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
356 438 630 797 893 767 913 1,000 1,134 1,376 1,491 1,852
455 369 512 612 757 722 834 868 942 1,037 1,232 1,513
Operating Profit -100 69 118 185 136 45 78 132 192 340 259 339
OPM % -28% 16% 19% 23% 15% 6% 9% 13% 17% 25% 17% 18%
2 4 4 3 9 7 8 5 0 7 42 59
Interest 54 15 19 16 10 7 10 10 9 8 8 9
Depreciation 24 16 16 16 28 30 27 23 27 36 45 52
Profit before tax -175 44 86 156 107 15 50 104 157 302 248 338
Tax % -1% -12% 15% 28% 23% 24% 28% 23% 23% 21% 25% 21%
Net Profit -176 49 74 112 83 11 36 80 121 239 187 265
EPS in Rs 1.19 1.87 2.67 1.92 0.22 0.80 1.87 2.95 5.76 4.51 5.88
Dividend Payout % -0% 10% 5% 4% 21% 23% 6% 3% 3% 4% 6% 0%
Compounded Sales Growth
10 Years: 16%
5 Years: 15%
3 Years: 18%
TTM: 24%
Compounded Profit Growth
10 Years: 19%
5 Years: 52%
3 Years: 30%
TTM: 44%
Stock Price CAGR
10 Years: 31%
5 Years: 25%
3 Years: 47%
1 Year: 76%
Return on Equity
10 Years: 20%
5 Years: 21%
3 Years: 22%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
50 52 52 53 53 41 41 41 41 41 41 45
Reserves -220 34 90 326 401 392 430 502 595 846 1,068 1,700
179 163 160 89 88 110 118 100 30 34 111 123
389 165 202 220 192 209 142 160 236 307 416 322
Total Liabilities 385 401 490 676 722 752 731 802 902 1,228 1,636 2,190
165 156 146 166 270 267 279 270 303 309 428 489
CWIP 0 0 0 0 0 0 0 0 0 12 3 7
Investments 0 0 0 0 0 0 0 0 0 0 0 1
220 245 344 510 452 484 451 533 599 907 1,205 1,694
Total Assets 385 401 490 676 722 752 731 802 902 1,228 1,636 2,190

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
-62 39 65 155 31 14 50 27 233 179 99
-3 -5 -4 -33 -123 -21 -39 -13 -60 -45 -42
57 -40 -29 17 -58 -3 3 -21 -114 -15 80
Net Cash Flow -9 -7 31 138 -150 -10 15 -7 60 118 137

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 116 109 98 84 89 118 71 64 78 72 97 82
Inventory Days 126 112 102 107 120 151 152 215 155 248 216 192
Days Payable 100 81 83 88 85 129 54 78 71 103 102 91
Cash Conversion Cycle 141 141 118 103 124 140 169 202 163 217 211 183
Working Capital Days -218 37 48 55 95 130 117 133 94 110 138 133
ROCE % -306% 45% 38% 45% 23% 4% 11% 19% 25% 39% 24% 22%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.60 49.00 43.85
3.28 4.69 5.05 4.34 3.14 2.64 2.59 3.46 4.04 4.06 4.23 15.11
0.67 0.30 0.30 0.34 0.56 0.53 0.41 0.47 0.94 0.95 0.96 1.46
47.80 46.76 46.40 47.07 48.05 48.58 48.75 47.82 46.77 46.38 45.79 39.57

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls